Goldman Sachs Upgrades Twist Bioscience to Buy, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has upgraded Twist Bioscience (TWST) from Neutral to Buy and increased the price target from $25 to $45.
January 17, 2024 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience's stock rating has been upgraded by Goldman Sachs from Neutral to Buy, with a significant increase in the price target from $25 to $45.
An upgrade from a prominent investment bank like Goldman Sachs typically leads to increased investor confidence and can drive up the stock price in the short term. The substantial raise in the price target from $25 to $45 reflects a strong positive outlook for the company, which may lead to a bullish sentiment among investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100